Merck: EU approves Keytruda in new indications
(CercleFinance.com) - Merck today announced that the European Commission has approved Keytruda as a treatment for five new indications, including certain colorectal cancers, advanced or recurrent endometrial carcinoma, and unresectable or metastatic stomach, small bowel or biliary tract cancers.
As a single agent, Keytruda acts on mismatches (dMMR) or high microsatellite instability (MSI-H).
Keytruda monotherapy has shown high objective response rates and durability of response in patients with five different types of MSI-H/dMMR cancers, an immuno-oncologist in Paris said.
This approval enables Keytruda monotherapy to be marketed in the 27 European Union (EU) Member States plus Iceland, Liechtenstein, Norway and Northern Ireland.
Copyright (c) 2022 CercleFinance.com. All rights reserved.